Exclusive Summary

• Scarce core target with top-tier progress: UB701 is a global Top 3 small molecule P53 reactivator targeting the TP53 Y220C mutation, possessing massive potential to fill the void in the pan-solid tumor market.
• Best-in-Class efficacy potential: UB701 demonstrates robust tumor growth inhibition in multiple models at significantly lower exposure levels (only 1/10 to 1/4) compared to the primary competitor, PC14586.
• Breakthrough in brain metastasis: With significantly increased brain penetration, it addresses a critical unmet clinical need by targeting central nervous system metastasis, particularly in lung and breast cancers.
• Superior safety profile and low PK risk: It exhibits enhanced predicted human pharmacokinetics with a low risk of CYP and hERG inhibition, generating a broad safety margin exceeding 10-fold based on toxicology studies.
• Clinical Phase I PoC demonstrated: Ongoing Phase I trials have early signs of dose-dependent enhancement of specific biomarkers (e.g., GDF-15), making it a high-value asset for early-stage global license-out.

Asset Materials

Contact Us for Full Materials